Eli Lilly Opens Retatrutide Expanded Access Beyond the First Patient
TL;DR: Lilly confirmed 3 Aug 2026 it will open retatrutide pre-approval access beyond one patient, with published eligibility criteria.
What Did Eli Lilly Announce on 3 August 2026?
Roughly six weeks after STAT News first reported that Eli Lilly had granted a single 79-year-old patient compassionate-use access to retatrutide (LY3437943) outside its Phase 3 programme, the company confirmed on Monday 3 August 2026 that it will open pre-approval access to additional patients.[1] Lilly told STAT it is "actively reviewing requests from health care providers" and has built a formal expanded access programme, stating: "for a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA's guidance."[1]
The announcement follows requests from a number of doctors who reached out to Lilly after the original single-patient case became public, seeking similar access for their own patients.[1] A corresponding protocol, Provide Pre-approval Expanded Access of LY3437943, is now registered on ClinicalTrials.gov under identifier NCT07629401, giving the programme a formal regulatory record beyond the single compassionate-use grant reported in June.[3]
Who Qualifies for the Retatrutide Expanded Access Programme?
Reported eligibility criteria are narrower than a standard clinical trial and specific to severe, treatment-resistant cases. According to STAT's reporting, patients must be:[1]
Age and disease severity
18 years or older, with refractory obesity despite tolerating the highest approved dose of an existing obesity therapy.
Complication burden
At least two serious or life-threatening obesity-related complications for which the patient is receiving active medical care.
No trial alternative
Unable to participate in an ongoing retatrutide clinical trial or a comparable investigational treatment programme.
This mirrors the general FDA framework for expanded access (sometimes called "compassionate use") under 21 CFR 312.310, which permits a seriously ill patient to receive an investigational drug outside a trial when no comparable approved therapy exists and the treating physician and sponsor agree the potential benefit justifies the risk.[4] What changed on 3 August is the scale: rather than a single named case handled ad hoc, Lilly now has a defined cohort protocol that multiple qualifying patients and their physicians can apply against.
How Does This Follow the June 2026 Case?
We covered the original case in detail in our retatrutide expanded access explainer: on 23 June 2026, STAT reported that a 79-year-old patient with refractory obesity, obstructive sleep apnoea and pulmonary hypertension had received retatrutide outside the TRIUMPH Phase 3 programme under a single-patient compassionate-use grant.[2] That case drew scrutiny partly because of unverified speculation about the patient's identity, and partly because it raised the question of whether other similarly situated patients might seek the same access.[2]
June 2026: single-patient grant
One named compassionate-use case, handled individually under 21 CFR 312.310, disclosed after the fact by STAT reporting.
August 2026: cohort programme
A published eligibility framework and formal ClinicalTrials.gov registration (NCT07629401), open to multiple qualifying patients whose physicians apply on their behalf.
The distinction matters for how the programme is regulated: a single-patient expanded access request is reviewed case by case, while an intermediate-size or cohort expanded access protocol like NCT07629401 requires its own FDA-reviewed protocol, informed consent process and safety monitoring plan, applied consistently across every patient who enrols under it.
Does This Mean FDA Approval Is Imminent?
No. Expanded access and standard FDA approval are separate regulatory tracks that run independently of one another. Lilly confirmed on 23 July 2026 that it still intends to file a Biologics License Application (BLA) for retatrutide in Q1 2027, having pushed the filing back from an earlier target to allow more time for manufacturing and quality-control (CMC) data — a decision unrelated to trial results.[5] That timeline has not moved as a result of this week's announcement.
Expanded access does not shorten formal review. Opening a broader pre-approval access programme lets a defined group of seriously ill patients receive an unapproved drug outside a trial. It has no bearing on the standard BLA review clock that begins once Lilly files, and it is not evidence the FDA has pre-judged that filing.
Retatrutide's Phase 3 TRIUMPH programme has continued reporting positive topline data through the summer — see our coverage of the TRIUMPH-2 and TRIUMPH-3 results (23 July 2026) and the BLA filing delay — but the expanded access programme sits alongside that clinical evidence base rather than substituting for it.
What Should UK Researchers Take From This?
Lilly's expanded access programme is a US patient-treatment pathway for its own branded investigational drug, administered under FDA oversight to named patients with a treating physician. It has no relationship to the UK research-reagent market and no bearing on the Human Medicines Regulations 2012 or MHRA guidance governing research-use compounds sold in Great Britain and Northern Ireland.
Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent, entirely separate from Lilly's clinical drug-development programme, its compassionate-use grants, or any pathway for human dosing. Our product exists for laboratory and preclinical research only.
Retatrutide is referenced here for regulatory-news context only. Where supplied by Velox Peptides, it is a research reagent, not a medicine, and has not been evaluated by the MHRA or FDA in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- STAT News. Eli Lilly to offer retatrutide access given earlier to just one patient. 3 August 2026. statnews.com
- STAT News. Eli Lilly gave mysterious access to weight loss drug to 79-year-old patient. 23 June 2026. statnews.com
- ClinicalTrials.gov. Provide Pre-approval Expanded Access of LY3437943. NCT07629401. clinicaltrials.gov
- U.S. Food and Drug Administration. Expanded Access (Compassionate Use) - Investigational Drugs. fda.gov
- CNBC. Eli Lilly will file for approval of retatrutide obesity drug in 2027. 23 July 2026. cnbc.com
Frequently Asked Questions
What did Eli Lilly announce on 3 August 2026?
Eli Lilly confirmed to STAT News that it will open pre-approval expanded access to retatrutide to additional patients, roughly six weeks after it emerged the company had granted single-patient compassionate use to one 79-year-old in June 2026. Lilly said it is "actively reviewing requests from health care providers" under a defined protocol.
Who is eligible for the retatrutide expanded access programme?
Reported eligibility criteria require patients to be 18 or older, have refractory obesity despite tolerating the highest approved dose of existing obesity therapy, have at least two serious or life-threatening obesity-related complications for which they are receiving active care, and be unable to enrol in an ongoing retatrutide trial or a comparable investigational treatment.
How is this different from the single-patient case reported in June?
The June 2026 case was a single-patient compassionate-use grant under 21 CFR 312.310, reported by STAT on 23 June. The August announcement establishes a cohort-level expanded access programme with published eligibility criteria and a formal ClinicalTrials.gov registration (NCT07629401), allowing multiple qualifying patients rather than one named individual to apply.
Does opening expanded access mean FDA approval is imminent?
No. Expanded access and FDA approval are separate regulatory tracks. Lilly still targets a Q1 2027 Biologics License Application submission, confirmed 23 July 2026. Expanded access lets a defined group of seriously ill patients access an unapproved drug outside a clinical trial; it does not shorten or guarantee the standard review process that follows a BLA filing.
Does this affect UK research-reagent supply?
No. Lilly's expanded access programme is a US patient-access pathway for its own investigational pharmaceutical product and has no bearing on UK research-reagent supply, which is governed by the Human Medicines Regulations 2012 and MHRA guidance. Velox Peptides supplies retatrutide strictly as an HPLC-verified in vitro research reagent, entirely separate from Lilly's clinical drug-development programme.